41 unknown, 9 completed, 6 recruiting, 3 active not recruiting. 64 Phase 1, 39 Phase 2.
Follow camrelizumab: new trials by email Literature Review of camrelizumab trials Research Report on camrelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer CircFam53B-219aa DC vaccine, camrelizumab - Breast Neoplasms | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 48 | 2024-12-01 | 2024-07-31 |
| Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas Camrelizumab, Palbociclib(100mg), Palbociclib(125mg) - Esophageal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | West China Hospital | 6 | 2024-10-27 | 2026-04-02 |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Linperlisib, Camrelizumab, Pegaspargase - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2024-04-14 | 2024-04-19 |
| Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | CNBG-Virogin Biotech (Shanghai) Ltd. | 36 | 2023-11-30 | 2023-11-15 |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-11-01 | 2023-11-08 |
| Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg - Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 6 | 2023-10-31 | 2024-07-23 |
| Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 36 | 2023-08-25 | 2023-08-24 |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 170 | 2023-08-01 | 2023-08-08 |
| A SHR-1210 BE Study on Healthy Subjects SHR-1210 - Advanced Tumors | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2023-07-04 | 2024-12-31 |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma adebrelimab, camrelizumab plus apatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 52 | 2023-07-01 | 2024-02-21 |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) A1:SG with SHR3680, A2:SG, B1:SG with SHR1210 - TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 125 | 2023-07-01 | 2023-07-03 |
| A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer Camrelizumab and Apatinib Plus GP - Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 49 | 2023-04-27 | 2026-06-22 |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2023-02-23 | 2023-04-28 |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion bevacizumab and camrelizumab - Malignant Pleural Effusion | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 55 | 2022-08-01 | 2022-04-15 |
| A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor Linperlisib Tablet - Advanced Solid Tumor | Phase 1 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 118 | 2022-06-30 | 2022-06-23 |
| Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Camrelizumab - Esophageal Neoplasm, Immunotherapy | Phase 1 / Phase 2 | Active not recruiting | Fujian Medical University Union Hospital | 25 | 2021-11-10 | 2025-11-19 |
| Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma hyperbaric oxygen therapy plus Camrelizumab - Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable | Phase 1 | Unknown | Zhang Bi Xiang, MD | 20 | 2021-10-30 | 2023-12-19 |
| Gut Microbiota Reconstruction for NSCLC Immunotherapy Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Platinum based chemotherapy - Non-Small Cell Lung Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 20 | 2021-09-01 | 2021-08-17 |
Showing 20 of 64. Sign in to see all of them.
Carcinoma, Hepatocellular (6) · Triple Negative Breast Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Esophageal Squamous Cell Carcinoma (3) · Biliary Tract Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Recurrence (2) · Colorectal Neoplasms (1) · Disease Progression (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Lung Diseases (1)
Jiangsu HengRui Medicine Co., Ltd. (8) · Chinese PLA General Hospital (6) · Fudan University (4) · Ruijin Hospital (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · West China Hospital (3) · Sun Yat-sen University (2) · Zhongshan Hospital Xiamen University (2) · Atridia Pty Ltd. (1) · Beijing Tongren Hospital (1) · CNBG-Virogin Biotech (Shanghai) Ltd. (1) · China Medical University, China (1) · Fujian Medical University Union Hospital (1) · HRYZ Biotech Co. (1) · Harbin Medical University (1)
China (53) · Australia (1)
Jun Zhang, MD & Ph. D (3) · Erwei Song, M.D., Ph.D. (2) · Yanqiao Zhang, PhD (2) · Baorui Liu, M.D & Ph.D (1) · Chengzhi Zhou, MD (1) · Chun Chen, Dortor (1) · Dongsheng Zhang, M.D., Ph.D. (1) · Erwei Song, M.D.. Ph.D. (1) · Feng Wang (1) · Haitao Zhao, MD (1) · Huiping Li, PhD (1) · Jiafu JI, Doctor (1) · Jian-Ming Xu, M.D. (1) · Jin Zhou, MD.,PhD. (1) · Juan Li, MD (1)
PMID 41121239, PMID 30213452, PMID 15126782, PMID 15875784, PMID 17340590, PMID 18172173, PMID 18971936, PMID 21296855, PMID 21742485, PMID 22575238, PMID 23452187, PMID 23918952, PMID 24357284, PMID 24948466, PMID 25800393, PMID 25838374, PMID 25838375, PMID 26515495, PMID 26901407, PMID 27324428, PMID 27827318, PMID 27959684, PMID 28197365, PMID 28408606, PMID 28583311, PMID 28796558, PMID 29368638, PMID 29614760, PMID 30293387, PMID 30348638, PMID 30835255, PMID 32256049, PMID 32487569, PMID 32719455, PMID 34725214, PMID 35105939, PMID 35596181, PMID 36104359, PMID 36184642, PMID 36725836, PMID 3806806, PMID 38290515, PMID 38347177, PMID 39962074, PMID 40346524, PMID 41077611, PMID 41225509, PMID 41803866, PMID 42215704, PMID 9933432